A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders: A report of the Rome Foundation Working Team on cross-cultural, multinational research

Neurogastroenterology and Motility

Volumn 26, Issue 10, 2014, Pages 1368-1385

  Schmulson, M ^a   Corazziari, E ^b   Ghoshal, U C ^c   Myung, S J ^d   Gerson, C D ^e   Quigley, E M M ^f   Gwee, K A ^g   Sperber, A D ^h  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^d University of Ulsan College of Medicine   (South Korea)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g Dept Medicine Endocrinol Diabet   (Singapore)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

CAM; IBS; Available medications; Cross cultural, multinational trials; Diagnostic procedures; Expenditures; Functional gastrointestinal disorders; Healthcare coverage; Registration process

Indexed keywords

DIGESTIVE SYSTEM FUNCTION DISORDER; ENDOSCOPY; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; INDIA; IRRITABLE COLON; ITALY; MEXICO; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; SOCIAL CLASS; SOCIAL SECURITY; SOUTH KOREA; ECONOMICS; ETHNOLOGY; GASTROINTESTINAL DISEASES; HEALTH CARE DELIVERY;

DELIVERY OF HEALTH CARE; GASTROINTESTINAL DISEASES; HUMANS; INDIA; ITALY; MEXICO; REPUBLIC OF KOREA;

EID: 84908236203     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12402     Document Type: Review

References (63)

1. Murray CJ, Frenk J. A framework for assessing the performance of health systems. Bull World Health Organ 2000; 78: 717-31.
2. Evans DB, Tandon A, Murray CJ, Lauer JA. Comparative efficiency of national health systems: cross national econometric analysis. Br Med J 2001; 323: 307-10.
3. Richardson J, Wildman J, Robertson IK. A critique of the World Health Organisation's evaluation of health system performance. Health Econ 2003; 12: 355-66.
4. Lauer JA, Knox Lovell CA, Murray CJ, Evans DB. World health system performance revisited: the impact of varying the relative importance of health system goals. BMC Health Serv Res 2004; 4: 19.
5. Svoronos T, Mate KS. Evaluating large-scale health programmes at a district level in resource-limited countries. Bull World Health Organ 2011; 89: 831-7.
6. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 2011; 89: 412-21.
7. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21 e4.
8. Schmulson M, Lopez-Colombo A. Epidemiology of irritable bowel syndrome. In: Simren M, Tornblom H, eds. Irritable Bowel Syndrome: Diagnosis & Management, 1st edn. London: Future Medicine Ltd, 2013: 5-20.
9. Koloski NA, Jones M, Wai R, Gill RS, Byles J, Talley NJ. Impact of persistent constipation on health-related quality of life and mortality in older community-dwelling women. Am J Gastroenterol 2013; 108: 1152-8.
10. Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm 2013; 19: 755-64.
11. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 2011; 40: 11-9.
12. Sperber A, Gwee KA, Hungin AP, Whitehead H, the Working Team members. Rome Foundation Working Team Report. Conducting Multinational, Cross-cultural Research in the Functional GI Disorders and Fostering Multinational Research Networks: The Rome Foundation; 2014 Jannuary 20th. Available at: http://www.romecriteria.org/committees/WorkingTeamFinalReport_Jan%202014.pdf
13. BRICS. 2013. Available at: http://en.wikipedia.org/wiki/BRICS
14. Move Over, BRICs. Here Come the MISTs. Bloomberg Business week, Markets & Finance. 2012. Available at: http://www.businessweek.com/articles/2012-08-09/move-over-brics-dot-here-come-the-mists
15. Goldman Sachs's MIST Topping BRICs as Smaller Markets Outperform. Bloomberg. 2012. Available at: http://www.bloomberg.com/news/2012-08-07/goldman-sachs-s-mist-topping-brics-as-smaller-markets-outperform.html
16. Kim HP, Park EC, Hahm MI. The gap between physicians and the public in satisfaction with the National Health Insurance system in Korea. J Korean Med Sci 2012; 27: 579-85.
17. Ministry of Health and Family Welfare. Report of the National Commission on Macroeconomics and Health. Government of India. In: Lal PG, Byword Editorial Consultants, eds. New Delhi: Cirrus Graphics Private Limited. August 2005.
18. INEGI. Principales resultados del Censo de Población y Vivienda 2010. Instituto Nacional de Estadística y Geografía. Censo de Población y Vivienda 2010. Mexico: INEGI, 2010.
19. World Review Mexico. 2012. Available at: http://www.medicinadigital.com/index.php/salud-p%C3%BAblica-em%C3%A9xico/22570-fortalecer-el-sistema-de-salud-reto-del-gobiernoentrante.html
20. Conozca qué factores críticos impulsan al Sistema de Salud Mexicano. 2012. Avaibale at: http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=4cd39a26fa563310VgnVCM100000ed152ca2RCRD&vgnextchannel=343879d7f269e210VgnVCM10000071812ca2RCRD
21. Knaul FM, González-Pier E, Gómez-Dantés O, García-Junco D, Arreola-Ornelas H, Barraza-Lloréns M, Sandoval R, Caballero F et al. Hacia la cobertura universal en salud: protección social para todos en México. Salud Publica Mex 2013; 55: 207-35.
22. Ubaldi E. La rilevanza dei disturbi funzionali intestinali in medicina generale. Proceedings of Le malattie funzionali gastrointestinali. Dal sintomo alla terapia NeuroGastroenterologia 2010; 16: 85.
23. Bellini M, Tosetti C, Costa F, Biagi S, Stasi C, Del Punta A, Monicelli P, Mumolo MG et al. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Dig Liver Dis 2005; 37: 934-9.
24. Park JM, Choi MG, Cho YK, Lee IS, Kim JI, Kim SW, Chung IS. Functional gastrointestinal disorders diagnosed by Rome III questionnaire in Korea. J Neurogastroenterol Motil 2011; 17: 279-86.
25. Jung HK, Kim YH, Park JY, Jang B, Young Park S, Nam M-H, Choi M-G. Economic burden of Irritable Bowel Syndrome; the analysis of a national health insurance database covering the entire population. Neurogastroenterol Motil 2010; 22: 58.
26. Shah SS, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in the general population in Mumbai. Indian J Gastroenterol 2001; 20: 103-6.
27. Ghoshal UC, Abraham P, Bhatt C, Choudhuri G, Bhatia SJ, Shenoy KT, Banka NH, Bose K et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol 2008; 27: 22-8.
28. Leyva-Jiménez R, Olvera-Torres P, Alvarez-Córdova MM, Alcántar-Saldívar EL. [Irritable bowel syndrome in adults attending to medical offices at UMF]. Rev Med Inst Mex Seguro Soc 2006; 44: 473-9.
29. División Técnica de Información Estadística en Salud. Motivos de consulta en medicina familiar en el IMSS, 1991-2002. Rev Med Inst Mex Seguro Soc 2003; 41: 441-8.
30. 50% de las consultas de los servicios de gastroenterología son por colitis. 2012. Available at: http://elportalslp.com.mx/noticia.php?id=3314
31. Córdova Pluma VH, Ibarrola Calleja JL, Hegewisch Orozco ME, Argüelles Domenzain P, González MV, de la Torre Sánchez MC, Castillo González FA, Maldonado Vásquez MA et al. Frecuencia de síndrome de intestino irritable en la consulta de medicina interna y cirugía general en tres centros de atención médica de la Ciudad de México. Med Int Mex 2008; 24: 120-4.
32. Ghoshal UC, Abraham P, Bhatia SJ, Misra SP, Choudhuri G, Biswas KD, Chakravartty K, Dadhich S et al. Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study. Indian J Gastroenterol 2013; 32: 369-75.
33. Gwee KA, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, Chua AS, Lu CL et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1189-205.
34. Remes Troche JM, Bernal Reyes R, Valladares Lepine MA, Alonso Larraga O, Gomez Escudero O, Melendez Mena D. [Gastroenterology diagnosis and treatment guidelines of irritable bowel syndrome; clinical features and diagnostic criteria]. Rev Gastroenterol Mex 2009; 74: 58-62.
35. Ortiz-Garrido O, Schmulson M. Los médicos en Latinoamérica reportan utilizar con mayor frecuencia los más recientes criterios de Roma III para diagnosticar síndrome de intestino irritable en la clínica. ¿Pero conocen realmente los criterios? Rev Gastroenterol Mex 2012; 77(Suppl. 3): 95.
36. Schmulson M, Lopez-Colombo A, Mendoza-Gomez A, Montiel-Jarquin A, Morgan D. The Rome III Adult Questionnaire in Spanish-Mexico has a low sensitivity for identifying IBS and higher sensitivity for uninvestigated dyspepsia. Gastroenterology 2012; 143(Suppl. 1): S-829.
37. Tosetti C, Bellentani S, Benedetto E, Ubaldi E, Cardin F, Bozzani A; DyGeP Investigators and Researchers. The management of patients with new onset of upper gastro-intestinal symptoms in primary care. Dig Liver Dis 2010; 42: 860-4.
38. Bellentani SBP, Petrella S, Tata C, Armocida C, Marchegiano P, Saccoccio G, Manenti F. A simple score for the identification of patients at high risk of organic diseases of the colon in the family doctor consulting room. The Local IBS Study Group. Fam Pract 1990; 7: 307-12.
39. Su A, Chang L. IBS bowel habits and associated symptoms: forming a clearer picture. Gastroenterology 2013; 144: 239-42.
40. Jung HK, Kim YH, Park JY, Jang BH, Park SY, Nam MH, Choi MG. Estimating the burden of irritable bowel syndrome: Analysis of a nationwide Korean database. J Neurogastroenterol Motil 2014; 20: 242-52.
41. Valenzuela J, Alvarado J, Cohen H, Damiao A, Francisconi C, Frugone L, González JC, Hernández A et al. [Latin-American consensus document on irritable bowel syndrome]. Gastroenterol Hepatol 2004; 27: 325-43.
42. Schmulson M. Se debe buscar enfermedad celiaca en pacientes con síndrome de intestino irritable? Posición en contra. In: Uscanga L, Bernal-Reyes R, eds. Escrutinio de enfermedades del aparato digestivo. Mexico DF: Intersistemas, S.A. de C.V., 2009: 217-22.
43. Remes Troche JM, Sánchez Vargas LA, Thomas Dupont P, Torres-Aguilera M, Ramírez-Cervantes KL, Azamar-Jacome AA, Aedo-Garcés MR, Meixueiro-Daza A et al. Prevalencia de anticuerpos relacionados a enfermedad celíaca (EC) en pacientes con diagnóstico de síndrome de intestino irritable. Un estudio de casos y controles. Rev Gastroenterol Mex 2012; 77(Suppl. 3): 1.
44. Lahner E, Bellentani S, De Bastiani R et al. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. United Eur Gastroenterol J 2013; 1: 385-93.
45. CPMP/EWP/785/97 March 2003 and the EMA/CHMP/172616/2012. 2012. Available at: www.EMEA
46. Chen W, Li D, Wilson I, Chadwick VS. Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J Gastroenterol Hepatol 2002; 17: 987-93.
47. Korean Ministry of Food and Drug Safety. 2010. Available at: http://www.mfds.go.kr/eng/index.do.
48. Ghoshal UC, Abraham P, Bhatia SJ, Misra SP, Choudhuri G, Biswas KD, Chakraborty K, Dadhich S et al. Comparison of Manning, Rome I, II, III and Asian diagnostic criteria: report of a Multi-centric Indian Irritable Bowel Syndrome (MIIBS) study. J Gastroenterol Hepatol 2012; 27(Suppl. 5): P19.
49. Singh P, Agnihotri A, Pathak MK, Shirazi A, Tiwari RP, Sreenivas V, Sagar R, Makharia GK. Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center. J Neurogastroenterol Motil 2012; 18: 324-31.
50. Available at: http://www.cdsco.nic.in/
51. Guía práctica clínica para el diagnóstico y tratamiento del síndrome de colon irritable. México: Secretaría de Salud, 2008. Available at: http://www.centec.salud.gob.mx/interior/gpc.html
52. Schmulson MJ, Noble Lugo A, Valenzuela de la Cueva VM, De Arino Suarez M, Guillermo Denis LA, Ramos Narvaez FA. [Gastroenterology diagnosis and treatment guidelines of irritable bowel syndrome; treatment]. Rev Gastroenterol Mex 2009; 74: 63-70.
53. Moléculas Nuevas, 2012. Available at: http://www.cofepris.gob.mx/AS/Paginas/Mol%C3%A9culas%20nuevas/Tr%C3%A1mites-Mel%C3%A9culas-Nuevas.aspx
54. Lahner E, Bellentani S, De Bastiani R, Tosetti C, Arullani P, Bruno Annibale B. Use of alternative and complementary therapies in patients with functional gastrointestinal disorders: an Italian survey. Europ J Integrative Medicine 2012; 4(Suppl. 4): 172.
55. Carmona-Sanchez R, Tostado-Fernandez FA. [Prevalence of use of alternative and complementary medicine in patients with irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease]. Rev Gastroenterol Mex 2005; 70: 393-8.
56. Fortea J, Prior M. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden. J Med Econ 2013; 16: 329-41.
57. Dibonaventura MD, Prior M, Prieto P, Fortea J. Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom. Clin Exp Gastroenterol 2012; 5: 203-12.
58. Neri L, Basilisco G, Corazziari E, Stanghellini V, Bassotti G, Bellini M, Perelli I, Cuomo R. LIRS Study Group. Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterol J. 2014; 2: 138-47.
59. Korean National Health Insurance Corporation. Available at: http://www.nhic.or.kr/english/main.html.
60. Schmulson Wasserman MJ, Valdovinos Díaz MA. [Utilization of medical resources for patients with irritable bowel syndrome in a tertiary hospital]. Rev Gastroenterol Mex 1998; 63: 6-10.
61. Schmulson MJ. Limited diagnostic testing can decrease the direct economic impact of irritable bowel syndrome. Rev Med Chil 2008; 136: 1398-405.
62. Mateos G, Vargas JA, Tamayo de la Cuesta JL, Crespo Y, Jiménez A, Remes-Troche JM, López-Colombo A, López-Alvarenga JC, Schmulson M. The economic burden of IBS in a Latin-American population. A report from the Mexican- IBS Working Group. Gastroenterology 2011; 140(Suppl. 1): S1362.
63. Schmulson M, Mateos G, Vargas JA, López-Alvarenga JC, Remes-Troche JM, Soto-Pérez JC, Orozco A, Jiménez A et al. How is symptom severity associated with work absenteeism and productivity in IBS-Rome III patients? A report from the Mexican IBS working group. Gut 2009; 58(Suppl. II): P0395.